Therapeutic Solutions International Demonstrates Potent and Selective Destruction of Tumor Blood Vessels by Leveraging Pre-Existing Natural Anti-Xenogeneic Antibodies

Rhea-AI Summary

Therapeutic Solutions International (OTC Markets: TSOI) has announced new data supporting its innovative immunotherapy derived from inducible pluripotent stem cells (iPSC). This approach aims to selectively destroy cancer-associated blood vessels by harnessing the alpha1,3-galactosyltransferase enzyme. Unlike previous therapies, which activate 1 in 1,000,000 immune cells, this method stimulates up to 1 in 100. The technology promises a consistent cell therapy product, crucial for collaborations with Big Pharma and regulatory progress.

Positive

• New patent filing for innovative immunotherapy that effectively targets cancer-associated blood vessels.
• Significantly higher immune response activation compared to traditional therapies.
• Consistent and reproducible iPSC-derived cell therapy products enhance partnership potential with major pharmaceutical companies.

Negative

• None.

ELK CITY, Idaho, March 29, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data and a new patent filing demonstrating this new immunotherapy derived from inducible pluripotent stem cells (iPSC) induces potent and selective killing of cancer associated blood vessels. 

In contrast to other approaches, the current immunotherapy involves transfection of the enzyme alpha1,3-galactosyltransferase into the iPSC, following that iPSC cells are transformed into tumor endothelial-like cells and used for immunization. The introduction of the alpha1,3-galactosyltransferase gene causes the cells to express to Gal alpha 1-3Gal beta-4-GlcNAc (alpha Gal). Alpha Gal is one of the most potent immune stimulating molecules in nature, evoking one of the most potent immune responses known to man. 

"Previous immunotherapies activate and recruit approximately 1 out of 1,000,000 immune cells to attack cancer whereas the current approach activates as much as 1 out of 100 immune cells," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "It is well known in the field of xenotransplantation that humans possess 1 to 5% of their antibodies directed towards the alpha Gal epitope which is found in all animals with the exception of monkeys and humans. This is God's way of stopping inter-species transplantation. By directing this potent antibody response against tumor blood vessels our preliminary data supports feasibility of this novel approach in attacking the Achilles heel of cancer, which is angiogenesis."

Side by side comparison between the currently described approach and approaches, such as placental derived cancer endothelial vaccines like ValloVax by Batu Biologics, suggest significantly higher level of immunity towards cancer angiogenesis can be obtained with the currently described approach.

"The advantage of using iPSC technology is that we are generating consistent and reproducible cell therapy products, which are two features essential for partnership with Big Pharma as well as progression through the regulatory process," said Famela Ramos, Vice President of Business Development. "What we are talking about here is the production of a Third Generation Cellular Immunotherapy for cancer."

"Our Company's philosophy has always been to leverage existing propensities of the body as opposed to fighting the body," stated Timothy Dixon, President and CEO of the Company and co-inventor. "I commend our collaborating scientists for the completely novel concept of leveraging existing premade antibodies as a new way of shutting down the formation of new blood vessels by the cancer." 

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ 

ir@tsoimail.com

View original content:http://www.prnewswire.com/news-releases/therapeutic-solutions-international-demonstrates-potent-and-selective-destruction-of-tumor-blood-vessels-by-leveraging-pre-existing-natural-anti-xenogeneic-antibodies-301257387.html

SOURCE Therapeutic Solutions International

FAQ

What is the new therapy announced by Therapeutic Solutions International (TSOI)?

The new therapy is an immunotherapy derived from inducible pluripotent stem cells (iPSC) targeting cancer-associated blood vessels.

How does the new immunotherapy from TSOI compare to traditional methods?

The new therapy activates up to 1 in 100 immune cells, significantly higher than traditional methods that activate 1 in 1,000,000.

What role does alpha1,3-galactosyltransferase play in TSOI's therapy?

It is an enzyme introduced into iPSC to create tumor endothelial-like cells that enhance immune response against cancer blood vessels.

When was the new data on TSOI's immunotherapy released?

The new data was announced on March 29, 2021.

What is the significance of iPSC technology in TSOI's therapy?

iPSC technology enables the production of consistent and reproducible cell therapy products, which is essential for regulatory approval and industry partnerships.